PRESS RELEASE: 52-Week Study Finds ONGLYZA(TM) (saxagliptin) When Added to Metformin Was Non-Inferior to Titrated Glipizide When Added to Metformin in Reducing Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus
26th Jun 2010 15:00
ORLANDO--(BUSINESS WIRE)--June 26, 2010-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a 52-week Phase 3b study in adults with type 2 diabetes who had inadequate glycemic control on metformin therapy plus diet and exercise. This study found th
Read morePRESS RELEASE: 52-Week Study Finds ONGLYZA(TM) -2-
26th Jun 2010 15:00
Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improvin
Read morePRESS RELEASE: ONGLYZA(TM) (saxagliptin) With -2-
26th Jun 2010 14:30
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews
Read morePRESS RELEASE: ONGLYZA(TM) (saxagliptin) With Metformin as Initial Combination Therapy Provided 76-Week Long-Term Glycemic Control in Treatment-Naive Adults With Type 2 Diabetes
26th Jun 2010 14:30
ORLANDO, Fla.--(BUSINESS WIRE)--June 26, 2010-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results up to 76-weeks from a Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy with metformin, which produced long-term glycemic improveme
Read moreLondon midday: Stormy weather for BP
25th Jun 2010 12:01
Mining stocks and BP have combined to spoil what was a firm start by London's blue-chip stocks, with even the weather now appearing to have it in for the beleaguered UK oil giant. Mining stocks such as ENRC, Lonmin and Kazkhmys suffer chunky falls but these are dwarfed by BP shares, which are havin
Read moreEU Panel Adopts Positive Opinion On Vpriv From Shire
25th Jun 2010 10:33
LONDON (Dow Jones)--The Committee for Medicinal Products for Human Use, or CHMP, said Friday it has adopted a positive opinion on Vpriv (velaglucerase alfa), from Shire Pharmaceutical Ireland Ltd, an orphan medicine intended for the treatment of Gaucher disease adding that Vpriv might constitute an
Read moreLondon open: Healthy start for blue chips
25th Jun 2010 08:56
London has shrugged off Dow Jones' triple-digit fall overnight and made decent headway this morning. Banks are higher after a jam-packed financial stability report from the Bank of England that covered everything from savings ratios to the threat of the eurozone. The market sems to have focused on
Read moreAstraZeneca Buys Back 300,000 Shares At 2985P
25th Jun 2010 08:00
LONDON (Dow Jones)--AstraZeneca PLC (AZN.LN) said Friday it has purchased for cancellation 300,000 of its ordinary shares at a price of 2985 pence per share. MAIN FACTS: -Shares closed Thursday at 2997 pence. -By Tommy Stubbington, Dow Jones Newswires; 44-20-7842-9268; tommy.stubbington
Read moreLondon pre-open: No sign of Wall St. hangover
25th Jun 2010 07:43
After the Dow Jones suffered a triple-digit fall overnight there were fears that London might go the same way, but traders are predicting the FTSE 100 will open a little higher, up 16 points at 5,116. BP has spent another $350,000 (£234,000) on the Gulf of Mexico oil disaster since Monday, taking t
Read moreAstraZeneca: FDA Resets Review Date For Motavizumab To Aug 27
25th Jun 2010 07:11
LONDON (Dow Jones)--AstraZeneca PLC (AZN.LN), a global biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines, said Friday its biologics unit MedImmune received notice that the U.S. Food and Drug Administration has reset the deci
Read moreFDA resets review date for Astra drug
25th Jun 2010 07:04
Anglo-Swedish drugs group AstraZeneca said the US Food and Drug Administration (FDA) has reset the decision date for its review of Astra's respiratory disease treatment, motavizumab. The date has been reset to 27 August 2010. Motavizumab was reviewed by the FDA's Antiviral Drugs Advisory Committe
Read moreBroker tips: Glaxo, Micro Focus, DSG
24th Jun 2010 13:00
If GlaxoSmithKline pulls the trigger and launches its Lucozade brand in the US, it could be the key to unlocking shareholder value and rectify the stock's underperformance relative to fellow pharmaceuticals giant AstraZeneca, Panmure Gordon reckons. The size of the US market for soft drinks is arou
Read morePfizer Ends Pediatric Bipolar-Drug Trial Before It Starts
24th Jun 2010 12:36
(This article was originally published Wednesday.) By Thomas Gryta and Peter Loftus Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Pfizer Inc. (PFE) has decided not to proceed with a late-stage clinical trial of its antipsychotic drug Geodon in children with bipolar disorder, a controve
Read moreN AMERICAN MORNING BRIEFING: Recovery Fears To Hit Stocks
24th Jun 2010 11:44
DJIA Futures 10191.50 -33.50 -0.30% S&P 500 Futures 1081.60 -5.80 -0.50% Nasdaq Futures 1860.13 -13.63 -0.70% Above are as of 0615 ET FTSE 100 5144.85 -33.67 -0.70% Xetra DAX 6160.65 -43.87 -0.70% CAC40 3602.90 -38.89 -1.10% Above are as of 0
Read moreN AMERICAN MORNING BRIEFING: Recovery Fears To Hit Stocks
24th Jun 2010 11:43
DJIA Futures 10191.50 -33.50 -0.30% S&P 500 Futures 1081.60 -5.80 -0.50% Nasdaq Futures 1860.13 -13.63 -0.70% Above are as of 0615 ET FTSE 100 5144.85 -33.67 -0.70% Xetra DAX 6160.65 -43.87 -0.70% CAC40 3602.90 -38.89 -1.10% Above are as of 0
Read more